Clinical trials: CtDNA
Breast Cancer
Circulating Tumor DNA After Neoadjuvant Chemotherapy
Trial assessing the prognostic value of ctDNA mutations from samples taken sequentially in patients with invasive breast cancer initially treated with neoadjuvant chemotherapy and whose tumor is not in complete histological…
- Trial name
- ALIENOR (NCT03357120)
- Testing
- Follow-up after neoadjuvant chemotherapy
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Institut Bergonié
Non-small Cell Lung Cancer Stage III, PDL1 Gene Mutation
Study of Antitumor Immune Response After cCRT and IO Treatment in Non-resectable III Stage NSCLC Patients
Observational, multicenter, one-arm, non-comparative study. Data will be recorded in a retrospectively manner. The study will be based on secondary data collected from patient clinical chart completed by the doctor during routine…
- Trial name
- SIENNA (NCT06634199)
- Testing
- Durvalumab
- Where
- 22 sites in Spain
- Volunteers
- 50 people
- Sponsor
- Fundación GECP
Advanced Hodgkin Lymphoma, Classic Hodgkin Lymphoma
Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma
This phase II trial tests how well personalized reduction of chemotherapy (nivolumab, doxorubicin, vinblastine and dacarbazine) based on circulating tumor deoxyribonucleic acid (ctDNA) evaluation works for treating patients with…
- Conditions
- Advanced Hodgkin Lymphoma, Classic Hodgkin Lymphoma, Lugano Classification Stage III Hodgkin Lymphoma AJCC v8, Lugano Classification Stage IV Hodgkin Lymphoma AJCC v8
- Trial name
- NCT06745076
- Testing
- Biospecimen Collection, Computed Tomography, Dacarbazine
- Where
- 6 sites in United States
- Volunteers
- 125 people
- Sponsor
- University of Washington
Cancer
Analysis of Circulating Tumor Markers in the Blood (ALCINA)
Exploratory study on blood-borne biological markers and their correlation with clinical and pathological characteristics.
- Trial name
- ALCINA (NCT02866149)
- Testing
- Blood sampling, Tumor sampling, Stool sampling
- Where
- 5 sites in France
- Volunteers
- 682 people
- Sponsor
- Institut Curie
Early Detection of Cancer
The PREDICT Study: Prospective Early Detection In a Population at High-risk for Common Malignant Tumor
This is a observational, multicenter study, monitoring the circulating tumor DNA (ctDNA) in people who is at risk of cancers，assessing the sensitivity and specificity of ctDNA detection in early screening of pan-carcinoma.
- Trial name
- NCT04405557
- Where
- 8 sites in China
- Volunteers
- 757 people
- Sponsor
- Geneplus-Beijing Co. Ltd.
Breast Cancer
Women In Steady Exercise Research - Window of Opportunity for Exercise and Tumor Biology
The primary aim is to examine changes in tumor perfusion, oxygen saturation, and tumor physiology before and following acute physical activity in breast cancer patients.
- Trial name
- WISER-WIN (NCT05428709)
- Testing
- Acute Exercise
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Milton S. Hershey Medical Center
Breast Cancer
Clinical Application of ctDNA in Early Screening of Breast Cancer
The investigators aim to evaluate the possibility of clinical application of ctDNA detection in peripheral blood of normal people, benign breast disease patients and breast cancer patients, so as to act as the new techniques or…
- Trial name
- NCT03973034
- Testing
- Low depth whole genome sequencing
- Volunteers
- 300 people
- Sponsor
- Peking Union Medical College Hospital
Pancreatic Ductal Adenocarcinoma (PDAC)
Intraperitoneal Paclitaxel With NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis
This goal of this clinical trial is to learn whether the drug combination of intraperitoneal paclitaxel (chemotherapy given directly into the abdominal cavity) and intravenous NALIRIFOX (chemotherapy given into a vein, including…
- Trial name
- NCT07030283
- Testing
- Paclitaxel, NALIRIFOX
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Colorado, Denver
Breast Cancer
Treatment Intermittent Periods Based on ctDNA-MRD（Circulating Tumor DNA-minimal Residual Disease） Status in Advanced HER2-Positive Breast Cancer
Breast cancer seriously threatens the health of women worldwide. The HER-2-positive subtype accounts for approximately 15% to 20%, featuring strong invasiveness and poor prognosis.
- Trial name
- NCT07132502
- Testing
- ctDNA MRD
- Volunteers
- 24 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Pancreatic Adenocarcinoma, Pancreatic Cancer
The Influence of Secretin Stimulated Pancreatic Secretion on ctDNA Expression in Patients With Pancreatic Ductal Adenocarcinoma: The Role of Biomarkers in Determining the Prognosis of Pancreatic Ductal Adenocarcinoma
The goal of this study is to assess the influence of pancreatic secretion stimulation by intravenously administered secretin on circulating tumor DNA in patients with pancreatic ductal adenocarcinoma.
- Trial name
- NCT06807112
- Testing
- Intravenously administered secretin
- Where
- Czechia
- Volunteers
- 39 people
- Sponsor
- Charles University, Czech Republic
Adenocarcinoma Esophagus
Circulating Tumor DNA (ctDNA) in Locally Advanced Esophageal and Gastroesophageal (GE) Junction Adenocarcinoma
This is an observational study to determine the feasibility of assessing tumor response utilizing ctDNA in patients of locally advanced esophageal and gastroesophageal junction (LA-EA/GEJ) cancer undergoing total neoadjuvant…
- Trial name
- TRACT DNA (NCT05067842)
- Testing
- Circulating tumor DNA(ctDNA) level measurement
- Where
- United States
- Sponsor
- Medical College of Wisconsin
Adenocarcinoma of Lung
ctDNA-MRD Based Adjuvant Targeted Therapy for EGFR Positive Stage I Lung Adenocarcinomas
The purpose of this study is to determine the feasibility and effectiveness of ctDNA-MRD based adjuvant furmonertinib therapy in EGFR mutation-positive stage I lung adenocarcinoma patients after complete surgical resection.
- Trial name
- NCT05079022
- Testing
- Furmonertinib
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking University People's Hospital
Colorectal Cancer Stage II, Colorectal Cancer Stage III
the Role of ctDNA in Predicting the Recurrence Risk of Colorectal Cancer
The purpose of this study was to observe the relationship between ctDNA as a molecular marker of colorectal cancer and the risk of postoperative recurrence.
- Trial name
- NCT05131243
- Testing
- Chemotherapy time
- Volunteers
- 100 people
- Sponsor
- Fujian Cancer Hospital
Breast Cancer, Triple Negative Breast Cancer
Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
The purpose of this study is to determine if a combination of two drugs sacituzumab govitecan and atezolizumab works as a treatment for residual cancer in the breast or lymph nodes and have circulating tumor DNA in the blood.
- Conditions
- Breast Cancer, Triple Negative Breast Cancer, Residual Cancer, Circulating Tumor DNA
- Trial name
- NCT04434040
- Testing
- Atezolizumab, Sacituzumab govitecan
- Where
- 7 sites in United States
- Volunteers
- 40 people
- Sponsor
- Dana-Farber Cancer Institute
Colorectal Cancer, Pancreatic Adenocarcinoma
Circulating Tumor DNA Exposure in Peripheral Blood
This is a prospective, multi-center, blinded feasibility study. The objective of this study is to test the feasibility of the detection of tumor DNA of a variety of tumors in peripheral blood using a novel process for the…
- Conditions
- Colorectal Cancer, Pancreatic Adenocarcinoma, Gastric Cancer, Hepatocellular Carcinoma
- Trial name
- NCT03517332
- Where
- 6 sites in United States, Switzerland
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Quantgene Inc.
Diffuse Large B Cell Lymphoma (DLBCL)
Dynamic CtDNA-guided Targeted Therapy in DLBCL
This is a prospective, single-arm, noninferiority trial involving patients with previously untreated CD20-positive DLBCL. The aim of this study is to determine the efficacy and safety of treatment stratified based on ctDNA…
- Trial name
- NCT06748521
- Testing
- R-CHOP + X
- Volunteers
- 108 people
- Sponsor
- Ruijin Hospital
SCLC
Next-generation Sequencing of Small Cell Lung Cancer to Identify Susceptibility Gene and to Assess Treatment
Participants will be consented into the study after they are found to meet the study inclusion criteria. The clinical staff will schedule a tissue biopsy and a blood draw for the participant to give NGS(Next-generation…
- Trial name
- NCT03244904
- Volunteers
- 80 people
- Sponsor
- Fujian Cancer Hospital
High-grade Serous Ovarian Cancer, Circulating Tumor DNA
CtDNA as a Novel Biomarker of Treatment Efficacy in Patients With Ovarian Cancer
This study is a prospective observational clinical trial. Patients who were diagnosed and treated for the first time were enrolled and their surgical pathology was confirmed to be high-grade serous ovarian cancer.
- Trial name
- NCT05027828
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
HER2-positive Breast Cancer
Asian Multicenter Prospective Study in HER2 Positive Early Breast Cancer for Detecting MRD by ctDNA;HARMONY Study
This study will assess minimal residual disease (MRD) in HER2-positive early breast cancer patients in Asian countries. The purpose is to evaluate the relation between the detection rate of MRD and recurrence.
- Trial name
- NCT05433753
- Where
- Japan
- Volunteers
- 60 people
- Sponsor
- National Cancer Center, Japan
Cancer of the Lung, Lung Cancer
Circulating Tumor DNA in Patients at High Risk for Lung Cancer
Patients who are about to undergo a diagnostic or therapeutic bronchoscopy or thoracic surgery without a distant history of cancer will have their blood drawn for measurement of circulating tumor DNA (ctDNA) to validate the…
- Conditions
- Cancer of the Lung, Lung Cancer, Lung Neoplasms, Adenocarcinoma of the Lung
- Trial name
- NCT02715102
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Pathway Genomics